SynBiotic Past Earnings Performance
Past criteria checks 0/6
SynBiotic's earnings have been declining at an average annual rate of -48.7%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 30.6% per year.
Key information
-48.7%
Earnings growth rate
-37.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 30.6% |
| Return on equity | -76.6% |
| Net Margin | -275.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How SynBiotic makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 4 | -11 | 3 | 0 |
| 31 Dec 22 | 8 | -24 | 6 | 0 |
| 31 Dec 21 | 9 | -13 | 2 | 0 |
| 31 Dec 20 | 5 | -1 | 1 | 0 |
| 31 Dec 19 | 0 | 0 | 0 | 0 |
Quality Earnings: SBX is currently unprofitable.
Growing Profit Margin: SBX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SBX is unprofitable, and losses have increased over the past 5 years at a rate of 48.7% per year.
Accelerating Growth: Unable to compare SBX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SBX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: SBX has a negative Return on Equity (-76.57%), as it is currently unprofitable.